Visual and refractive outcomes following implantation of a new trifocal intraocular lens

Michael Lawless1,2*, Chris Hodge1,3, Joe Reich4, Lewis Levitz4, Uday K. Bhatt4, Colm McAlinden5, Kate Roberts4 and Timothy V. Roberts1,2

Abstract

Background: Independence from all optical aids, and freedom from unwanted symptoms, following cataract and lens surgery remains the ultimate goal of both patient and surgeon. The development of trifocal IOL technology provides an ever-increasing range of options. The purpose of our study is to understand the predictability, safety and efficacy of a new trifocal intraocular lens (IOL) following cataract or refractive lens exchange (RLE) surgery.

Methods: This was a retrospective consecutive case series of patients undergoing cataract extraction or RLE followed by implantation of the Alcon IQ Panoptix IOL. Pre and postoperative refractive and visual parameters were recorded and evaluated. As the cohort followed a normal distribution, standard parametric tests were used. Paired t-test was used to compare the difference between target and postoperative refractive errors. The incidence of intraoperative and postoperative complications was also reported.

Results: The IOL was implanted in 66 eyes of 33 patients. Mean postoperative spherical equivalent (SE) refraction was -0.08 ± 0.25 dioptres (D). This was not significantly different from the target refraction (p = 0.841). Sixty-five percent of patients were within ± 0.25 D of the target SE refraction with 100% within ± 0.50 D of intended correction. Mean postoperative uncorrected distance visual acuity (UDVA) was 0.01 ± 0.10 LogMAR. All patients achieved an unaided distance acuity of 20/40 or better postoperatively. Binocularly, 100% saw 0.20 LogMAR or better at near without correction and 88.9% achieved this level for uncorrected intermediate visual acuity. No intraoperative complications were noted. Five patients complained of moderate haloes in the early postoperative period.

Conclusion: The AcrySof IQ Panoptix IOL provides functional uncorrected visual acuity at distance, intermediate and near positions. Our results remain equivalent with existing trifocal IOL outcomes and provide surgeons with a further IOL alternative for the patient motivated to obtain true spectacle independence. Surgeons should consider individual reading and working requirements when counselling patients preoperatively to optimise postoperative patient satisfaction.

Keywords: Trifocal, Trifocal, IOL, Cataract, Refractive lens exchange

* Correspondence: michael.lawless@visioneyeinstitute.com.au

1 Vision Eye Institute, Level 3 270 Victoria Avenue Chatswood, Sydney, NSW 2067, Australia
2 Sydney Medical School, University of Sydney, Sydney, NSW, Australia

Full list of author information is available at the end of the article
Background
The use of presbyopia correcting intraocular lenses (IOLs) has shown modest growth since their introduction in the 1980s with an approximate 2.4% share of the current global IOL market [1]. High add powers dominated early multifocal models providing excellent near vision. A shift in functional vision requirements however has more recently seen a move towards lower add powers enabling good intermediate acuity (i.e. for use with desktop computers) and augmented distance vision [2, 3]. The recent development of trifocal IOLs provides an expanded range of unaided close vision allowing for further benefits over multifocal IOL predecessors [4–9]. Most available trifocal models utilise a diffractive platform albeit with an emphasis upon slightly different focal points for near and intermediate activities (between 35 to 45 cm and 60 to 80 cm, respectively). These new options provide the ophthalmologist with an opportunity to customise the approach to individual patient requirements.

The Acrysof IQ Panoptix IOL (Alcon Surgical, Inc.) represents the most recent addition to the presbyopia-correcting trifocal IOL market. To our knowledge, we provide the first significant case series of patients undergoing cataract or refractive lens extraction with implantation of the Panoptix IOL describing the visual and safety outcomes in a retrospective, multi-centre cohort.

Methods
A retrospective assessment of consecutive patients undergoing implantation of the Acrysof IQ Panoptix IOL (Alcon Labs, Ft Worth, TX, USA) at 3 separate centres with 5 doctors (ML, JR, LL, TR, UB) was performed. The indication for surgery included both cataract and refractive lens extraction and implantation of the Panoptix IOL (Alcon Surgical, Inc.) at 3 separate centres with 5 doctors (ML, JR, LL, TR, UB) was performed. The surgery was performed in each case with topical anaesthesia. A femtosecond laser (LenSx, Alcon Ft Worth, TX, USA) was used to create the capsulorhexis and provide phacoemulsification. Corneal incisions were created manually through a 2.2 mm incision. The company provided “A” constant was used in conjunction with either Holladay II or Barrett Universal II IOL calculation formulas as per surgeon preference (Holladay IOL Consultant, Houston, TX, USA and www.apacrs.org/barrett_universal2 respectively). Refractive targets aimed for the minimum residual myopia. Postoperative medication regimen varied slightly between clinics however, each patient received a combination of anti-biotic and anti-inflammatory drops titrated through 4 weeks following surgery.

Patients returned for follow up at 1 day, 1 week, 4 weeks and 2 months. The most recent follow up visit details were recorded. Monocular and binocular uncorrected distance, intermediate (60 cm) and near (40 cm) visual acuities were collected. Visual acuity was converted from Snellen and Revised American Point-Type to LogMAR for analysis. Near and intermediate reading charts were limited to a minimum of N4 (Snellen equivalent approximately 20/25). Intraoperative and postoperative complications were recorded.

Data was collected in Microsoft Excel prior to analysis of basic parameters. The cohort followed a normal distribution therefore, standard parametric tests were used. The paired t-test was used to compare the difference between target spherical equivalent (SE) refraction and postoperative SE.

Results
Sixty-six eyes of 33 patients underwent cataract or clear lens extraction and implantation of an Acrysof IQ Panoptix IOL. Thirty-eight eyes underwent RLE (57.6%). Preoperative demographics are listed in Table 1. The mean length of follow up was 5.7 ± 1.7 weeks (range 4 to 9 weeks). The range of IOL powers used varied between 18.5 D and 27.5 D. The mean preoperative corneal cylinder was 0.50 ± 0.28 D (range 0 to 1.02 D).

Visual acuity
Mean preoperative corrected distance visual acuity (CDVA) was 0.09 ± 0.20 LogMAR(approximately 20/25).
Mean postoperative uncorrected distance visual acuity (UDVA) was 0.01 ± 0.10 LogMAR (approximately 20/20). 78.8% of patients achieved 20/20 UDVA or better. All patients achieved an UDVA of 20/40 or better postoperatively (Fig. 1).

The mean uncorrected intermediate visual acuity (UIVA) was 0.30 ± 0.14 LogMAR. Eighty-seven percent (87.9%) of patients achieved 0.40 LogMAR or better at 60 cm monocularly (N8 or J6 equivalent). Fifty percent (50%) of patients achieved 0.2 LogMAR or better (N6 or J2 equivalent) near unaided monocularly with 88.9% additionally achieving this level of vision binocularly at 60 cm at the final visit (Fig. 2). Sixty-three percent (63.6%) of patients achieved 0.14 LogMAR equivalent or better (N4 or J2) for monocular uncorrected near visual acuity (UNVA). Mean LogMAR UNVA was 0.18 ± 0.10. As expected, this increased significantly to 85.2% when both eyes were used together (mean 0.11 ± 0.04 LogMAR) (Fig. 2).

**Table 1** Preoperative characteristics

|                      | Mean (SD) | Min | Max |
|----------------------|-----------|-----|-----|
| Sphere (D)           | 1.66 (1.21) | -1.50 | +4.00 |
| Cylinder (D)         | -0.50 (0.39) | -1.50 | 0.00 |
| SE (D)               | 1.41 (1.21) | -1.75 | 4.00 |
| Mean keratometry (D) | 43.12 (1.25) | 40.81 | 45.39 |
| Corneal Astigmatism (D) | 0.46 (0.26) | 0.00 | 1.17 |
| Axial length (mm)    | 23.33 (0.82) | 21.44 | 24.66 |
| Anterior chamber depth (mm) | 3.05 (0.41) | 2.16 | 4.09 |

Mean postoperative uncorrected distance visual acuity (UDVA) was 0.01 ± 0.10 LogMAR (approximately 20/20). 78.8% of patients achieved 20/20 UDVA or better. All patients achieved an UDVA of 20/40 or better postoperatively (Fig. 1).

The mean uncorrected intermediate visual acuity (UIVA) was 0.30 ± 0.14 LogMAR. Eighty-seven percent (87.9%) of patients achieved 0.40 LogMAR or better at 60 cm monocularly (N8 or J6 equivalent). Fifty percent (50%) of patients achieved 0.2 LogMAR or better (N6 or J2 equivalent) near unaided monocularly with 88.9% additionally achieving this level of vision binocularly at 60 cm at the final visit (Fig. 2). Sixty-three percent (63.6%) of patients achieved 0.14 LogMAR equivalent or better (N4 or J2) for monocular uncorrected near visual acuity (UNVA). Mean LogMAR UNVA was 0.18 ± 0.10. As expected, this increased significantly to 85.2% when both eyes were used together (mean 0.11 ± 0.04 LogMAR) (Fig. 2).

**Complications**

No intraoperative complications were noted. Five patients complained of moderate glare or haloes through the initial postoperative period following the procedure. This however was not deemed sufficient to impair general activities nor require explant. All patients reported the phenomena diminishing by the subsequent postoperative visit (between 4 weeks to 3 months). There was no tendency to favour either the RLE or cataract group (3 patients/2 patients, respectively). Three patients described having to hold general text closer than prior to surgery, which necessitated minor adjustments to their work environment. Each of these patients confirmed the unaided vision remained more than adequate for their required tasks.

One eye (2.9%) in the RLE group lost 1 line of CDVA at 2 weeks due to drop-related corneal epithelial toxicity however, this resolved by the final visit. Additionally, 20.6% of RLE patients gained 1 line following surgery. Two eyes (7.1%) of one cataract patient did not obtain corrected distance vision (CDVA) of 0.00 LogMAR (20/20) post-operatively. This patient was found to have mild drusen following removal of the cataract that was not
apparent prior to surgery. The remaining 92.9% of patients gained between 1 and 6 lines of CDVA.

Discussion
Presbyopia correcting IOLs represent a significant clinical breakthrough for patients [11]. More recently, the introduction of trifocal IOL models provide surgeons with additional options when considering appropriate IOL selection. Comparative literature highlights the extended reading range provided by the three separate focal points of the trifocal IOLs compared to multifocal IOLs, leading to greater optical independence for all distances [9, 12, 13]. Conversely, the presence of two out-of-focus images increases the likelihood of haloes compared to a single out-of-focus image [14]. Optical bench comparisons between trifocal and multifocal IOLs confirm this albeit with some variation, attributed to IOL design [2, 11, 15–18]. Practical outcomes however, suggest that patient satisfaction remains high despite the increased presence of optical phenomena [19, 20]. Discussing the presence of haloes following trifocal IOL implantation is essential in any preoperative patient discussion.

Our study confirms the predictability and safety of the Panoptix IOL. Our outcomes are consistent with other non-toric trifocal studies. Kohnen previously published the initial findings for the lens reporting the initial outcomes of four patients with the Panoptix IOL. All patients achieved excellent unaided vision at all distances
albeit at 1 week follow up. Haloes and glare were present but not considered significant [10]. Separately, Kohnen et al. recently report a mean UDVA of 0.01 ± 0.11 LogMAR with the AtLisa trifocal IOL at 1 and 3 months [21]. Cochener et al. report an UDVA of 0.08 ± 0.11 LogMAR at 3 months following implantation of the FineVision IOL [22]. The follow-up study in 2014 indicated slightly improved results reporting a mean UDVA of 0.01 ± 0.06 LogMAR [5]. Sheppard et al. reported a mean monocular UDVA of 0.19 ± 0.09 LogMAR in a small sample at 2 months with the same IOL [23]. Law et al. found a mean UDVA of 0.05 ± 0.07 LogMAR at 6 months with the AtLisa trifocal IOL [19]. Mojzis et al. report a mean monocular UDVA of -0.03 ± 0.09 LogMAR at 6 months also for the AtLisa IOL [24]. Our results appear broadly equivalent with these findings (0.01 ± 0.10 LogMAR) at a similar postoperative time period. Considering the oft-described process of adaptation, it would be reasonably expected that the unaided vision in our cohort may continue to improve with further follow-up.

The different focal points between models makes direct comparisons of near and intermediate reading values more difficult [9]. The variation in reading tests and their respective limitations similarly impacts comparative references. Considering our results at the measured intermediate and near ranges however, the Panoptix IOL again provides similar findings. Jonkers et al. in a comparative study reported an UIVA and UNVA of 0.32 ± 0.15 and 0.15 ± 0.13 LogMAR, respectively, with the FineVision trifocal IOL [9]. In a small study of 22 eyes, Attia et al. report a mean UIVA and UNVA of 20/20.47 and 20/26.39 respectively, also with the FineVision IOL [6]. Further, Mojzis et al. report equivalent results at the intermediate range with the AtLisa trifocal 0.08 ± 0.10 LogMAR, replicated by Cochener and co-authors in their group with the same IOL model. UNVA in the latter reports were 0.20 ± 0.12 and -0.03 ± 0.04 LogMAR, respectively [5, 24]. Eighty-seven percent (87.9%) of our patients saw 0.20 LogMAR or greater at intermediate whilst 100% achieved this level or better binocularly. Patients who were found to have visual acuity worse than 0.00 LogMAR for distance notably had higher levels of postoperative refractive cylinder emphasizing the importance of limiting residual astigmatism. The use of arcuate incisions represents an option for surgeons, although it is expected a toric version of the trifocal will be available in early 2017 to further assist in minimizing overall postoperative refractive errors.

There were no intraoperative complications within our cohort. Five patients reported moderate haloes initially following surgery. This is consistent with other presbyopia correcting IOLs and with recent bench testing outcomes [25, 26]. Carson et al. suggested that the Panoptix Trifocal IOL showed equivalent or better performance in image quality and resolution compared with alternate trifocal IOLs. Importantly, all patients noted improvement in symptoms over time likely indicating the neuroadaptation process. Further, no patient felt that the haloes impeded their routine activities, suggesting that they were comfortable with the trade-off between symptoms and optical independence. Several patients noted that they had to make adjustments to their standard reading distances. In each case, the patient had slightly more residual myopia than expected, which may have brought forward the respective focal points. This confirms the importance of both accurate biometry calculations and preoperative counselling.

The Alcon Panoptix IOL is based on the same Acrysof 1-piece platform of the single focus IOL. This may have potential advantages over existing models. The stability of this platform has previously been reported [27–29]. Our early refractive outcomes based on the company provided “A” constant suggest that stability and consistency of lens positioning is readily achievable with the new model. In comparison, the AtLisa trifocal IOL is based on a plate-haptic design, which has previously correlated with additional movement within the capsular bag post-surgery [27, 28]. As previously shown across several optical simulations, tilt and decentration may have an impact upon visual performance [29, 30]. This may be exacerbated within presbyopia-correcting IOLs, which demand optimal positioning for maximum effective outcomes. Visual outcomes with the AtLisa trifocal remain excellent however and this putative advantage over plate haptic IOLs remains speculative [31]. The introduction of a toric version of the Panoptix model and further testing may provide additional results to support this hypothesis.

Conclusions
Our study represents the initial review of a new trifocal IOL. Overall, the IQ Panoptix IOL appears to provide both safety and visual profiles similar to current trifocal models without significant postoperative visual symptoms. Further prospective, case–control studies incorporating additional quality of vision and other subjective traits as well as reading measures may provide more appropriate comparisons with alternate trifocal models [32]. Irrespective of these studies, our results present a further IOL for surgeons to consider in their preoperative assessment with cataract and refractive lens patients who are seeking full optical independence. Particular consideration of patient reading and working requirements is required to optimise the lens model choice.
Additional file

**Additional file 1** Patient pre and post assessment results. (DOCX 27 kb)

Authors’ contributions
ML, JR, LL, UKB and TR carried out the surgical procedures. ML, CH, CM and KR were responsible for methodology, data collection and analysis. All authors were involved in the writing and review process and all approved the final manuscript.

Competing interests
The authors declare that they have no competing interests in the paper.

Author details
1 Vision Eye Institute, Level 3 270 Victoria Avenue Chatswood, Sydney, NSW 2067, Australia. 2 Sydney Medical School, University of Sydney, Sydney, NSW, Australia. 3 University of Technology, Sydney, NSW, Australia. 4 Vision Eye Institute, Melbourne, VIC, Australia. 5 University Hospitals Bristol, Bristol, UK.

Received: 21 September 2016 Accepted: 30 March 2017

Published online: 04 April 2017

References
1. Market Scope, Ophthalmic Market Perspectives. 2015. Marketscope LLC. (https://market-scope.com/) Accessed July 2016.
2. Ruiz-Alcocer J, Madrid-Costa D, García-Lázaro S, Ferrer-Blasco T, Montés-Micó R. Optical performance of two new trifocal intraocular lenses: through-focus modulation transfer function and influence of pupil size. Clin Exp Ophthalmol. 2014;42(3):271–6.
3. McAlinden C, Moore JE. Multifocal intraocular lens with a surface-embedded near section: Short-term clinical outcomes. J Cataract Refract Surg. 2011;37(9):441–5.
4. Ailo J, Montabaur P, Peña-Garcia P, Soria FA, Vega-Estrada A. Visual outcomes of a trifocal aspheric diffractive intraocular lens with microincision cataract surgery. J Refract Surg. 2013;29(11):756–61.
5. Cochener B, Vryghem J, Rozot P, Lesieur G, Heiremans J, Blanckaert JA, et al. Visual and refractive outcomes after implantation of a fully diffractive trifocal lens. Clin Ophthalmol. 2012;6:1421–7.
6. Sheppard AL, Shah S, Bhatt U, Bhogal G, Wolffsohn JS. Visual outcomes and subjective experience after bilateral implantation of a new diffractive trifocal intraocular lens. J Cataract Refract Surg. 2013;39(3):343–9.
7. Carballo-Alvarez J, Vazquez-Molini JM, Sanz-Fernandez JC, Garcia-Bella J, Polo V, Garcia-Feijoo J, et al. Visual outcomes after bilateral trifocal diffractive intraocular lens implantation. BMC Ophthalmol. 2015;15:26.
8. Lawless M, Ball SJ, Hodge C, Roberts TV, Chan C, Sutton G. Outcomes of femtosecond laser cataract surgery with a diffractive multifocal intraocular lens. J Refract Surg. 2012;28(12):859–64.
9. Jonker SM, Bauer NJ, Måholtchina NY, Berendschot TT, van den Biggelaar FJ, Nuijts RM. Comparison of a trifocal intraocular lens with a +3.0 D bifocal IOL: results of a prospective randomized clinical trial. J Cataract Refract Surg. 2015;41(8):1631–40.
10. Kohnen T. First implantation of a diffractive quadrifocal (trifocal) intraocular lens. J Cataract Refract Surg. 2015;41(10):2330–2.
11. Brito D, Hill WS, Hong K, Karakelle M. Optical bench performance of AcrySof® IQ ReSTOR®, AcrySof® IQ TrueVision™, and FineVision™ intraocular lenses. Clin Ophthalmol. 2014;8:2105–13.
12. Mojis P, Kluckova L, Majerova K, Lieveheova K, Plhova DP. Comparative analysis of the visual performance after cataract surgery with implantation of a bifocal or trifocal diffractive IOL. J Refract Surg. 2014;30(10):666–72.
13. Vasavada AR, Nath V, Raj S, Vasavada V, Vasavada S. Technology and Intraocular Lenses to Enhance Cataract Surgery Outcomes-Annual Review (January 2013 to January 2014). Asia Pac J Ophthalmol (Phila). 2014;3(5):068–21.
14. Carson D, Hill WS, Hong K. Optical bench performance of AcrySof® IQ ReSTOR®, AcrySof® IQ TrueVision™, and FineVision™ intraocular lenses. Clin Ophthalmol. 2014;8:2105–13.
15. Gatinel D, Pagnoulle C, Houbrechts Y, Gobin L. Design and qualification of a diffractive trifocal optical profile for intraocular lenses. J Cataract Refract Surg. 2011;37(11):2060–7.
16. Gatinel D, Houbrechts Y. Comparison of bifocal and trifocal diffractive and refractive intraocular lenses using an optical bench. J Cataract Refract Surg. 2013;39(7):1093–9.
17. Madrid-Costa D, Ruiz-Alcocer J, Ferrer-Blasco T, García-Lázaro S, Montés-Micó R. Optical quality differences between three multifocal intraocular lenses: bifocal low add, bifocal moderate add, and trifocal. J Cataract Refract Surg. 2013;39(11):749–54.
18. Alba-Bueno F, Vega F, Millán MS. Halos and multifocal intraocular lenses: origin and interpretation. Arch Soc Esp Oftalmol. 2014;89(10):397–404.
19. Law EM, Aggarwal RK, Kasaby H. Clinical outcomes with a new trifocal intraocular lens. Eur J Ophthalmol. 2014;24(4):501–8.
20. Kretz FT, Breyer D, Klabe K, Hagen P, Kaynak H, Koss MJ, et al. Clinical Outcomes After Implantation of a Trifocal Toric Intraocular Lens. J Refract Surg. 2015;31(8):504–10.
21. Kohnen T, Titke C, Böhm M. Trifocal Intraocular Lens Implantation to Treat Visual Demands in Various Distances Following Lens Removal. Am J Ophthalmol. 2016;161:71–7. e1.
22. Cochener B, Vryghem J, Rozot P, Lesieur G, Heiremans S, Blanckaert JA, et al. Visual and refractive outcomes after implantation of a fully diffractive trifocal lens. Clin Ophthalmol. 2012;6:1421–7.
23. Sheppard AL, Shah S, Bhatt U, Bhogal G, Wolffsohn JS. Visual outcomes and subjective experience after bilateral implantation of a new diffractive trifocal intraocular lens. J Cataract Refract Surg. 2013;39(3):343–9.
24. Mojis P, Peña-Garcia P, Lieveheova K, Ziaik P, Alid JL. Outcomes of a new diffractive trifocal intraocular lens. J Cataract Refract Surg. 2014;40(1):160–9.
25. Lee S, Choi M, Xu Z, Zhao Z, Alexander E, Liu Y. Optical bench performance of a novel trifocal intraocular lens compared with a multifocal intraocular lens. Clin Ophthalmol. 2016;10:1031–8.
26. Carson D, Xu Z, Alexander E, Choi M, Zhao Z, Hong X. Optical bench performance of 3 trifocal intraocular lenses. J Cataract Refract Surg. 2014;40(1):1361–7.
27. Bozukova D, Pagnoulle C, Jérôme C. Biomechanical and optical properties of 2 new hydrophobic platforms for intraocular lenses. J Cataract Refract Surg. 2013;39(9):1404–14.
28. Chang DF. Comparative rotational stability of single-piece open-loop acrylic and plate-haptic silicone toric intraocular lenses. J Cataract Refract Surg. 2008;34:1842–7.
29. Montés-Micó R, Ferrer-Blasco T, Cerviño A. Analysis of the possible benefits of aspheric intraocular lenses: review of the literature. J Cataract Refract Surg. 2009;35:172–81.
30. Madrid-Costa D, Pérez-Vives C, Ruiz-Alcocer J, Albarrán-Diego C, Montés-Micó R. Visual simulation through different intraocular lenses in patients with previous myopic corneal ablation using adaptive optics: effect of tilt and decentration. J Cataract Refract Surg. 2012;38:774–86.
31. Hirschhall N, Nishi Y, Crnej A, Kosty J, Gangvani V, Maurino V, et al. Capsular bag stability and posterior capsule opacification of a plate-haptic design microincision cataract surgery intraocular lens: 3-year results of a randomised trial. Br J Ophthalmol. 2013;97(12):1655–8.
32. Khadka J, McAlinden C, Pesudovs K. Quality assessment of ophthalmic questionnaires review and recommendations. Optom Vis Sci. 2013;90:720–44.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Thorough peer review
- Convenient online submission
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit